Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: The present invention relates to a non-oriented electrical steel sheet with excellent magnetism and a manufacturing method thereof. A non-oriented electrical steel sheet according to an embodiment of the present invention includes Si at 2.5 to 3.8 wt %, Al at 0.5 to 2.5 wt %, Mn at 0.2 to 4.5 wt %, C at 0.005 wt % or less (excluding 0 wt %), S at 0.005 wt % or less (excluding 0 wt %), N at 0.005 wt % or less (excluding 0 wt %), Nb at 0.004% or less (excluding 0 wt %), Ta at 0.0005 to 0.0025 wt %, and the balance of Fe and inevitable impurities.

Abstract: A non-oriented electrical steel sheet according to one embodiment of the present invention comprises, by weight %, 1.5 to 4.0% of Si, 0.7 to 2.5% of Al, 1 to 2% of Mn, 0.003 to 0.02% of Cu, at most 0.005% of S (not 0%), and the remainder comprising Fe and unavoidable impurities, and satisfies formulas 1 and 2 below. 150?[Mn]/[Cu]?250??[Formula 1] 3?[Cu]/[S]?7??[Formula 2] (here, [Mn], [Cu], and [S] represent Mn, Cu, and S contents (weight %), respectively.

Abstract: The present invention relates to a non-grain-oriented electrical steel sheet which is excellent in high-frequency iron loss, and a manufacturing method thereof. A non-grain-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes 2.5 to 3.8 wt % of Si, 0.5 to 2.5 wt % of Al, 0.2 to 4.5 wt % of Mn, 0.0005 to 0.02 wt % of As, 0.0005 to 0.01 wt % of Bi, the balance Fe, and inevitable impurities, and satisfies the following [Equation 1]. 0.3?[surface fine crystal grain diameter]×[fine grain formation thickness]×([As]/[Bi])?5.0??[Equation 1] In Equation 1, [surface fine crystal grain diameter] means an average particle diameter (?m) of fine crystal grains in an electrode surface layer of an electrical steel sheet, [fine grain formation thickness] means a thickness (mm) of an electrode surface layer in which fine crystal grains are formed, and [As] and [Bi] mean a composition (wt %) of As and a composition (wt %) of Bi, respectively.

Abstract: A non-oriented electrical steel sheet according to an embodiment of the present invention, comprises: Si: 2.0 to 3.5%, Al: 0.05 to 2.0%, Mn: 0.05 to 2.0%, In: 0.0002 to 0.003% by wt % and Fe and inevitable impurities as the remainder.

Abstract: A non-oriented electrical steel sheet according to an embodiment of the present invention may include, by weight, by weight, 2.0 to 3.5% of Si, 0.3 to 2.5% of Al, 0.3 to 2.5% of Mn, individually or in a total amount of 0.0005 to 0.03% of at least one of Ga and Ge, and the remainder including Fe and impurities, and may satisfy the following Formula 1. 0.2?([Si]+[Al]+0.5×[Mn])/(([Ga]+[Ge])×1000)?5.27??[Formula 1] ([Si], [Al], [Mn], [Ga] and [Ge] represent the content (% by weight) of Si, Al, Mn, Ga and Ge, respectively).

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: Provided is a method of setting an ultrasound preset, which includes displaying a selection window on a screen for selecting the preset corresponding to the selected probe upon at an event of selecting the probe, and to hide the selection window, in the case a user input for selecting the preset corresponding to the selected probe is not entered within a reference time.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: The present invention relates to an antibacterial dressing and a method for preparing the same. According to the present invention, there are provided an antibacterial dressing containing a rapid cell membrane-penetrating component that exhibits excellent bactericidal and antibacterial activities by disrupting the structure and synthesis of protein and nucleic acid, and a method for preparing the same.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: A non-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes at least one of 2.0 to 3.5% of Si, 0.3 to 3.5% of Al, 0.2 to 4.5% of Mn, 0.0030 to 0.2% of Sn, 0.0030 to 0.15% of Sb, 0.0040 to 0.18% of P, 0.0005 to 0.02% of Zn, and 0.0005 to 0.01% of Y for wt %, a remainder of Fe, and inevitable impurities, and satisfying Formula 1: 0.05?([Sn]+[Sb])/[P]?25??[Formula 1] (here, [Sn], [Sb], and [P] represent contents (wt %) of Sn, Sb, and P.

Abstract: A non-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes 2.0 to 4.0% of Si, 0.05 to 1.5% of Al, 0.05 to 2.5% of Mn, equal to or less than 0.005% of C (excluding 0%), equal to or less than 0.005% of N (excluding 0%), 0.001 to 0.1% of Sn, 0.001 to 0.1% of Sb, 0.001 to 0.1% of P, 0.001 to 0.01% of As, 0.0005 to 0.01% of Se, 0.0005 to 0.01% of Pb, 0.0005 to 0.01% of Bi, a remainder of Fe, and inevitable impurities, as wt %, wherein a Taylor factor (M) of each crystal grain included in a steel sheet is expressed in Formula 1, and an average Taylor factor value of the steel sheet is equal to or less than 2.75: M = ? ? CRSS [ Formula ? ? 1 ] (here, ? is a macro stress, and ?CRSS is a critical resolved shear stress.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 are provided. Antibodies that recognize specific epitopes of glycosylated PD-L1 protein and can block the binding of PD-L1 to PD-1 are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: A non-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes, by weight %, Si: 2.5 to 6.0%, Al: 0.2 to 3.5%, Mn: 0.2 to 4.5%, Cr: 0.01 to 0.2%, P: 0.005 to 0.08%, Mg: 0.0005 to 0.05%, and a remainder including Fe and inevitable impurities, while satisfying Equation 1 below, and formed with an inner oxidation layer of a 0.2 to 5 ?m thickness inside a base steel sheet. ?2.5?[P]/[Cr]?[Mg]×100?6.5??[Equation 1] (In Equation 1, [P], [Cr], and [Mg] respectively represent a content (by wt %) of P, Cr, and Mg.

Abstract: Disclosed are a display apparatus, where a component disposition area facing a component disposed on a lower end of a non-display area of a panel is removed in a lower substrate configuring the panel, and a method of manufacturing the same.

Abstract: Provided is a progress rate roll-up system for calculating a Level 3 progress rate based on a Level 4 progress rate. The progress rate roll-up system includes a Level association unit, a mapping association unit, and a Level 3 association unit. The progress rate roll-up system further includes at least one of a BEME database (DB), an EWS DB, an EIPS DB, a mapping DB, a EIPS_No_Group_MH DB, a CPVAL DB, and a EIPS_No_MH DB. Accordingly, because not only the Level 4 progress rate but also the Level 3 progress rate may be calculated, more accurate analysis data may be provided to complete a project within an allocated budget and a given construction period.

Abstract: Provided herein are molecules having an antigen binding fragment that immuno specifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immuno specifically binds to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.

Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as anti-BTN1A1 antibodies or anti-BTN1A1 ligand antibodies. Also provided herein are BTN1A1 ligands, such as Galectin-1, Galectin-9, Neuropilin-2, and B- and T-Lymphocyte Attenuator.